Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Novel Approaches in Cancer Study

Active Immunotherapy in cancer – Current Status

  • Open or Close Bakulesh Khamar*

    R&D Department, Cadila Pharmaceuticals Limited, India

    *Corresponding author: Bakulesh Khamar, R&D Department, Cadila Pharmaceuticals Limited, “Cadila Corporate Campus, Sarkhej - Dholka Road, Bhat, Ahmedabad, Gujarat, India-382210

Submission: February 21, 2018; Published: March 28, 2018

DOI: 10.31031/NACS.2018.01.000513

ISSN:2637-773X
Volume1 Issue3

Abstract

Immunotherapy is a fourth pillar in cancer management after surgery, radiotherapy and chemotherapy. Active immunotherapy works by inducing antigen specific immune response following its administration while checkpoint inhibitor works by reducing tumor induced immunosuppression and thereby utilizing pre-existing immune response. Adoptive cell therapy (ACT) is a type of personalized therapy wherein cells are harvested from a patient, expanded and reintroduced. The T cells are genetically modified in chimeric antigen receptor T cell (CAR-T) therapy while tumor infiltrating cells are used in in ACT and dendritic cells are used in dendritic cell (DC) vaccine. Vaccine induces T cell response against the antigen of interest. T cells available following single administration are higher in ACT compared to vaccine approach. CAR-T cells are found useful in refractory large B-cell lymphoma and refractory large B-cell precursor acute lymphoblastic leukemia. ACT is found useful in melanoma. Vaccines are approved for melanoma as a monotherapy and for non-small cell lung cancer in combination with chemotherapy.

Keywords: CAR-T therapy; ACT; Dendritic cell vaccine; Cancer vaccine; CD8+T cells; Active immunotherapy

Get access to the full text of this article


About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
  • info@crimsonpublishers.com
  • www.crimsonpublishers.com